Amanote Research
Register
Sign In
Letter: Distinct Hepatitis B Virus Relapse Rates After Discontinuing Tenofovir and Entecavir Therapy in Chronic Hepatitis B Patients
Alimentary Pharmacology and Therapeutics
- United Kingdom
doi 10.1111/apt.15150
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hepatology
Pharmacology
Gastroenterology
Date
March 28, 2019
Authors
Rui Huang
Renling Yao
Weihua Wu
Jian Wang
Chao Wu
Publisher
Wiley
Related search
Pgi14 Perceived Value Assessment of Entecavir Versus Tenofovir in Chronic Hepatitis B
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Tenofovir Plus Entecavir Combination Therapy for Chronic Hepatitis B With Nucleos(t)ide Analogue Failure
The European Research Journal
Letter: Hepatitis B Virus Reactivation in Patients With Chronic Hepatitis C During Direct-Acting Anti-Viral Therapy
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Hepatitis B Core-Related Antigen Levels Are Associated With Response to Entecavir and Peginterferon Add-On Therapy in Hepatitis B E Antigen–positive Chronic Hepatitis B Patients
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Molecular Characterization of Hepatitis B Virus X Gene in Chronic Hepatitis B Patients
Virology Journal
Virology
Infectious Diseases
Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients During Pregnancy and Post-Partum Follow-Up
PLoS ONE
Multidisciplinary
Long-Term Outcome of Entecavir Therapy in Chronic Hepatitis B With Cirrhosis
Clinical Gastroenterology and Hepatology
Hepatology
Gastroenterology
Obesity and Hepatocellular Carcinoma in Patients Receiving Entecavir for Chronic Hepatitis B
Clinical and molecular hepatology
Medicine
Hepatology
Molecular Biology
Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation
Gastroenterology
Hepatology
Gastroenterology
